DHTKD1 and neoplasm: Yun et al. developed an E1A/E1B double mutant replicating adenovirus Ad-ΔE1Bmt7 [28], and constructed a series of Ad-ΔE1Bmt7 armed with shRNAs targeting the key mediators in angiogenesis, the armed Ad-ΔE1Bmt7 demonstrated greater anti-tumor and anti-angiogenesis efficacy than Ad-ΔE1Bmt7 alone, when injected intratumorally in subcutaneous models of glioma, hepatocellular carcinoma and lung carcinoma [29–31].